A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder Clinical Trial

Official title:
A Phase II, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Status Completed

Clinical Trial Summary

This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Psychotic Disorders
Schizophrenia
Schizophrenia, Schizoaffective Disorder

Clinical Trial Details

NCT number	NCT04512066
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 2
Start date	September 8, 2020
Completion date	June 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02192593` - Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations	N/A
Completed	`NCT00224315` - Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial	Phase 4
Recruiting	`NCT02808533` - Topiramate and Schizophrenia: Effects on Weight and Psychopathology	N/A
Recruiting	`NCT06319170` - Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder	Phase 1
Terminated	`NCT03669640` - A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms	Phase 2